# Kevzara (sarilumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sarilumab

> The FDA approved Kevzara (sarilumab), sponsored by Sanofi (SNY), on May 22, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Kevzara (sarilumab) |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Polymyalgia Rheumatica](https://sec-api.dev/indications/polymyalgia-rheumatica) |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### May 22, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761037 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170522, review_priority STANDARD; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22

### February 28, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761037 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20230228, review_priority PRIORITY; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22

### June 10, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761037 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20240610, review_priority STANDARD; sponsor_name SANOFI SYNTHELABO; product KEVZARA (SARILUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761037%22

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Polymyalgia Rheumatica.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286214 (Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07286214

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Polymyalgia Rheumatica.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07286214 (Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-04 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07286214

## Same indication

- [Cosentyx (secukinumab)](https://sec-api.dev/pdufa/secukinumab) (NVS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sarilumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Kevzara (sarilumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sarilumab

```bibtex
@misc{secapidev_pdufa_sarilumab_20261116,
  title        = {Kevzara (sarilumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sarilumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sarilumab_20261116","title":"Kevzara (sarilumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sarilumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
